New cancer drug GEN1056 tested in first human trial

NCT ID NCT05586321

Completed Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Show contact details

Locations

ARENSIA Exploratory Medicine LLC

Tbilisi, Georgia
ARENSIA Exploratory Medicine Phase I Unit

Chisinau, Moldova
Centro Integral Oncologico Clara Campal

Madrid, Spain
Clinica Universidad de Navarra

Pamplona, Spain
Hospital Universitari Vall d'Hebron

Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz

Madrid, Spain
MD Anderson Cancer Centre

Madrid, Spain